Adaptive titration of renin–angiotensin–aldosterone system inhibitors in elderly HFpEF patients with hypertension: A retrospective cohort study of short-term effectiveness and tolerability
Background: Elderly patients with heart failure with preserved ejection fraction (HFpEF) and hypertension (HTN) may have poor tolerability to non-titrated fixed-dose renin-angiotensin-aldosterone system inhibitor (RAASi) therapy, with changes in renal function or electrolyte balance. Objectives: To evaluate whether a dynamic, protocol-guided RAASi titration strategy was associated with better short-term effectiveness and tolerability than a non-titrated fixed-dose regimen in elderly patients with HFpEF and HTN. Methods: This retrospective study included 130 elderly patients with HFpEF and HTN admitted between June 2022 and April 2025. Patients were categorized into an observation group (dynamic adaptive management, n=72) or a control group (non-titrated fixed-dose regimen, n=58) based on routine clinical practice. Both groups received standard symptomatic treatment. In the observation group, adaptive titration was supported by routine nursing monitoring, including blood pressure observation, medication education, reminders for renal-function and electrolyte testing and documentation of symptoms or adverse reactions. Cardiac function, blood pressure, renal function, electrolyte indices, adverse reactions, clinical effectiveness, medication adherence, and follow-up outcomes were compared after 1 month. Results: After 1 month, the observation group showed greater improvement in cardiac function and blood pressure control than the control group. Renal function and electrolyte indices remained more stable in the observation group. Adverse reactions were less frequent in the observation group than in the control group (9.72% vs. 25.86%), whereas the overall effective rate was higher (91.67% vs. 77.59%) (p<0.05). Medication adherence was better and disease recurrence was lower in the observation group (p<0.05), while readmission rates did not differ significantly (p>0.05). Conclusion: In elderly patients with HFpEF and HTN, a dynamic adaptive RAASi management strategy was associated with better short-term effectiveness and tolerability than a non-titrated fixed-dose regimen. Given the retrospective single-center design and short follow-up, these findings should be considered preliminary and require confirmation in larger prospective studies.
Authors
- Qi Wu (ORCID: https://orcid.org/0000-0002-0420-1454)
Publication Details
- Journal
- Pakistan Journal of Pharmaceutical Sciences
- Published
- 2026-11-21
- DOI
- https://doi.org/10.36721/pjps/2026.40.16272.1
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00